788 related articles for article (PubMed ID: 27600280)
1. [18F]FDG PET/CT-based response assessment of stage IV non-small cell lung cancer treated with paclitaxel-carboplatin-bevacizumab with or without nitroglycerin patches.
de Jong EE; van Elmpt W; Leijenaar RT; Hoekstra OS; Groen HJ; Smit EF; Boellaard R; van der Noort V; Troost EG; Lambin P; Dingemans AC
Eur J Nucl Med Mol Imaging; 2017 Jan; 44(1):8-16. PubMed ID: 27600280
[TBL] [Abstract][Full Text] [Related]
2. A randomized phase II study comparing paclitaxel-carboplatin-bevacizumab with or without nitroglycerin patches in patients with stage IV nonsquamous nonsmall-cell lung cancer: NVALT12 (NCT01171170)†.
Dingemans AM; Groen HJ; Herder GJ; Stigt JA; Smit EF; Bahce I; Burgers JA; van den Borne BE; Biesma B; Vincent A; van der Noort V; Aerts JG;
Ann Oncol; 2015 Nov; 26(11):2286-93. PubMed ID: 26347109
[TBL] [Abstract][Full Text] [Related]
3. The predictive value of
Mattoli MV; Massaccesi M; Castelluccia A; Scolozzi V; Mantini G; Calcagni ML
Radiat Oncol; 2017 Jan; 12(1):4. PubMed ID: 28057034
[TBL] [Abstract][Full Text] [Related]
4. The Predictive Value of Early In-Treatment
Usmanij EA; Natroshvili T; Timmer-Bonte JNH; Oyen WJG; van der Drift MA; Bussink J; Geus-Oei LF
J Nucl Med; 2017 Aug; 58(8):1243-1248. PubMed ID: 28336778
[No Abstract] [Full Text] [Related]
5. Early response to chemotherapy in patients with non-small-cell lung cancer assessed by [18F]-fluoro-deoxy-D-glucose positron emission tomography and computed tomography.
Novello S; Vavalà T; Levra MG; Solitro F; Pelosi E; Veltri A; Scagliotti GV
Clin Lung Cancer; 2013 May; 14(3):230-7. PubMed ID: 23276821
[TBL] [Abstract][Full Text] [Related]
6. Using positron emission tomography (PET) response criteria in solid tumours (PERCIST) 1.0 for evaluation of 2'-deoxy-2'-[18F] fluoro-D-glucose-PET/CT scans to predict survival early during treatment of locally advanced non-small cell lung cancer (NSCLC).
Fledelius J; Khalil AA; Hjorthaug K; Frøkiaer J
J Med Imaging Radiat Oncol; 2016 Apr; 60(2):231-8. PubMed ID: 26678718
[TBL] [Abstract][Full Text] [Related]
7. Changes in 18F-fluorodeoxyglucose and 18F-fluorodeoxythymidine positron emission tomography imaging in patients with non-small cell lung cancer treated with erlotinib.
Mileshkin L; Hicks RJ; Hughes BG; Mitchell PL; Charu V; Gitlitz BJ; Macfarlane D; Solomon B; Amler LC; Yu W; Pirzkall A; Fine BM
Clin Cancer Res; 2011 May; 17(10):3304-15. PubMed ID: 21364032
[TBL] [Abstract][Full Text] [Related]
8. Prospective Study of Serial Imaging Comparing Fluorodeoxyglucose Positron Emission Tomography (PET) and Fluorothymidine PET During Radical Chemoradiation for Non-Small Cell Lung Cancer: Reduction of Detectable Proliferation Associated With Worse Survival.
Everitt S; Ball D; Hicks RJ; Callahan J; Plumridge N; Trinh J; Herschtal A; Kron T; Mac Manus M
Int J Radiat Oncol Biol Phys; 2017 Nov; 99(4):947-955. PubMed ID: 29063854
[TBL] [Abstract][Full Text] [Related]
9. Imaging the early response to chemotherapy in advanced lung cancer with diffusion-weighted magnetic resonance imaging compared to fluorine-18 fluorodeoxyglucose positron emission tomography and computed tomography.
Tsuchida T; Morikawa M; Demura Y; Umeda Y; Okazawa H; Kimura H
J Magn Reson Imaging; 2013 Jul; 38(1):80-8. PubMed ID: 23239463
[TBL] [Abstract][Full Text] [Related]
10. Predictive and Prognostic Role of Metabolic Response in Patients With Stage III NSCLC Treated With Neoadjuvant Chemotherapy.
Castello A; Toschi L; Rossi S; Finocchiaro G; Grizzi F; Mazziotti E; Qehajaj D; Rahal D; Lopci E
Clin Lung Cancer; 2020 Jan; 21(1):28-36. PubMed ID: 31409523
[TBL] [Abstract][Full Text] [Related]
11. Is ¹⁸F-fluorodeoxyglucose positron emission tomography-based metabolic response superior to Response Evaluation Criteria In Solid Tumors-based response after two cycles of platinum-based chemotherapy in predicting clinical outcome of untreated patients with advanced non-small cell lung cancer?
Yang JJ; Wang SX; Zhong WZ; Xu CR; Yan HH; Wu YL
Nucl Med Commun; 2011 Dec; 32(12):1113-20. PubMed ID: 21934546
[TBL] [Abstract][Full Text] [Related]
12. Early detection of disease progression after palliative chemotherapy in NSCLC patients by (18)F-FDG-PET.
Tauhardt E; Reissig A; Winkens T; Freesmeyer M
Nuklearmedizin; 2014; 53(5):197-204. PubMed ID: 24986272
[TBL] [Abstract][Full Text] [Related]
13. [Correlation of histologic results with PET findings for tumor regression and survival in locally advanced non-small cell lung cancer after neoadjuvant treatment].
Schmücking M; Baum RP; Bonnet R; Junker K; Müller KM
Pathologe; 2005 May; 26(3):178-89. PubMed ID: 15800765
[TBL] [Abstract][Full Text] [Related]
14. Predictive and prognostic value of early response assessment using 18FDG-PET in advanced non-small cell lung cancer patients treated with erlotinib.
Tiseo M; Ippolito M; Scarlattei M; Spadaro P; Cosentino S; Latteri F; Ruffini L; Bartolotti M; Bortesi B; Fumarola C; Caffarra C; Cavazzoni A; Alfieri RR; Petronini PG; Bordonaro R; Bruzzi P; Ardizzoni A; Soto Parra HJ
Cancer Chemother Pharmacol; 2014 Feb; 73(2):299-307. PubMed ID: 24258456
[TBL] [Abstract][Full Text] [Related]
15. Utility of fluorodeoxyglucose-positron emission tomography in the identification of new lesions in lung cancer patients for the assessment of therapy response.
Obrzut S; Bykowski J; Badran K; Hayeri MR; Hoh CK
Nucl Med Commun; 2010 Dec; 31(12):1008-15. PubMed ID: 20926977
[TBL] [Abstract][Full Text] [Related]
16. Repeat 18F-FDG PET for monitoring neoadjuvant chemotherapy in patients with stage III non-small cell lung cancer.
Eschmann SM; Friedel G; Paulsen F; Reimold M; Hehr T; Budach W; Dittmann H; Langen HJ; Bares R
Lung Cancer; 2007 Feb; 55(2):165-71. PubMed ID: 17129635
[TBL] [Abstract][Full Text] [Related]
17. Predictive and Prognostic Value of Early Disease Progression by PET Evaluation in Advanced Non-Small Cell Lung Cancer.
Banna GL; Anile G; Russo G; Vigneri P; Castaing M; Nicolosi M; Strano S; Gieri S; Spina R; Patanè D; Calcara G; Fraggetta F; Marletta F; Stefano A; Ippolito M
Oncology; 2017; 92(1):39-47. PubMed ID: 27832654
[TBL] [Abstract][Full Text] [Related]
18. Chemotherapy response evaluation with 18F-FDG PET in patients with non-small cell lung cancer.
de Geus-Oei LF; van der Heijden HF; Visser EP; Hermsen R; van Hoorn BA; Timmer-Bonte JN; Willemsen AT; Pruim J; Corstens FH; Krabbe PF; Oyen WJ
J Nucl Med; 2007 Oct; 48(10):1592-8. PubMed ID: 17873138
[TBL] [Abstract][Full Text] [Related]
19. Are pretreatment 18F-FDG PET tumor textural features in non-small cell lung cancer associated with response and survival after chemoradiotherapy?
Cook GJ; Yip C; Siddique M; Goh V; Chicklore S; Roy A; Marsden P; Ahmad S; Landau D
J Nucl Med; 2013 Jan; 54(1):19-26. PubMed ID: 23204495
[TBL] [Abstract][Full Text] [Related]
20. Positron emission tomography in non-small-cell lung cancer: prediction of response to chemotherapy by quantitative assessment of glucose use.
Weber WA; Petersen V; Schmidt B; Tyndale-Hines L; Link T; Peschel C; Schwaiger M
J Clin Oncol; 2003 Jul; 21(14):2651-7. PubMed ID: 12860940
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]